Zai Lab (ZLAB)

Executive Summary

Zai Lab is a commercial-stage biopharmaceutical company headquartered in Shanghai and Cambridge, focused on oncology, immunology, neuroscience, and infectious disease. With a portfolio that includes eight marketed products and a pipeline spanning multiple therapeutic areas, the company leverages its capabilities in both China and the U.S. to address unmet medical needs. Key pipeline assets include ZL-1310 (a DLL3-targeting ADC) in Phase 3 for small-cell lung cancer, omadacycline plus moxifloxacin in Phase 3 for community-acquired bacterial pneumonia, and ZL-1102 (an anti-IL-17 antibody) in Phase 2 for plaque psoriasis. Zai Lab's strategy combines in-house discovery with global partnerships, positioning it to capture growth in China's expanding biotech market. Near-term catalysts include data readouts from late-stage trials and potential regulatory submissions for its pipeline candidates.

Upcoming Catalysts (preview)

• H1 2026Phase 3 topline data for omadacycline + moxifloxacin in community-acquired bacterial pneumonia70% success
• Q2 2026Phase 2 topline data for ZL-1102 gel in plaque psoriasis60% success
• H2 2026Phase 3 initiation and potential interim data for ZL-1310 in small-cell lung cancer50% success